Burimamide is an antagonist at the H<sub>2</sub> and H<sub>3</sub> histamine receptors. At physiological pH, it is largely inactive as an H<sub>2</sub> antagonist, but its H<sub>3</sub> affinity is 100x higher. It is a thiourea derivative.
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers. The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).